$6.110
-0.668 (-10.93%)收盤時
NRXS 資訊
NRXS 事件
NeurAxis Secures Coverage from Major Health Insurer
NeurAxis announced new medical policy coverage from a "major national health insurer" for Percutaneous Electrical Nerve Field Stimulation. The coverage spans multiple states and represents approximately 26M medical plan members, the company said in a statement. NeurAxis adds that its PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia, including associated nausea symptoms in patients eight years and older. CEO Brian Carrico said, "NeurAxis' growth is accelerating as we continue to execute on our strategy to expand payer coverage and scale commercialization of IB-Stim. With our national coverage footprint now exceeding 147 million lives, we are strengthening our commercial organization to capitalize on these significant gains. The recent appointment of Craig Blanchard as Chief Commercial Officer is a key investment in our next phase of growth, and we are actively hiring additional sales professionals to drive physician adoption and help more patients access treatment under these new coverage policies."
NeurAxis Up 7% to $7.01 After Announcing New Insurer Policy Coverage
NeurAxis up 7% to $7.01 after announcing new insurer policy coverage
NeurAxis Appoints Craig Blanchard as Chief Commercial Officer
NeurAxis announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Blanchard will oversee the Company's commercial functions, including sales and marketing. Previously, Blanchard served as Vice President of Product Strategy, Marketing and Field Clinical at NICO Corporation
Neuraxis Files to Sell 1.92M Shares of Common Stock
Neuraxis files to sell 1.92M shares of common stock for holders
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。